May 31, 2022
Article
Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.
Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.
SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.
Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.
Video
New data suggests there is no connection between ustekinumab and the risk of malignancies.
There are several companies preparing new treatments for recurrent C difficile infections.
There are several potential treatments on the horizon for C difficile infections.
May 26, 2022
At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.
Patients treated with ustekinumab are not at an increased risk of malignancies.
Treating the disease could reduce the risk of patient distress.
Joseph Goldberg, MD: Treating Mixed Feature Depression
M. Katherine Shear, MD: Addressing Grief After a Loss
Larry Culpepper, MD: The Challenge of Treating BPD
